

(51) International Patent Classification:
A61K 9/16 (2006.01) A61K 9/28 (2006.01)
A61K 9/20 (2006.01) A61K 31/397 (2006.01)

(21) International Application Number:
PCT/IB2015/052552

(22) International Filing Date:
8 April 2015 (08.04.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/977,806 10 April 2014 (10.04.2014) US

(71) Applicant (for all designated States except US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors; and
(71) Applicants (for US only): BOUILLOT, Philippe Michel Rene [FR/CH]; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH). REYNAUD, Emeric [FR/CH]; c/o Novartis Pharma AG, Postfach, 4002 Basel (CH).

(74) Agent: WIESSNER, Michael; Novartis Pharma AG, Patent Department, 4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

— with amended claims (Art. 19(1))

Date of publication of the amended claims: 10 December 2015

(54) Title: IMMUNOSUPPRESSANT FORMULATION

(57) Abstract: The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.